FDA Regulation of Nanotechnology: What Are the Rules of the Road?

FDA’s Nanotechnology Taskforce Report, issued in July 2007, identified numerous data gaps that the agency needs to fill, and recommended the issuance of guidance to clarify FDA’s regulatory approach to products derived through nanotechnology. This panel of senior FDA officials provided an update on FDA’s regulatory approach to nanotechnology at FDLI’s First Annual Conference on Nanotechnology Law, Regulation, and Policy.

Additional information available here.